



EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001
Tel: 022-35661373/35664530 Email: enquiries@ebnl.org Website: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

EBN/2022/S-LDF049

October 15, 2022

The Manager
The Department of Corporate Service
BSE Limited
Floor 25, Phiroze Jeejebhoy Towers
Dalal Street, Fort, Mumbai – 400 001,

Dear Sir / Madam,

Sub: Investor Grievance Report for the period July 01, 2022 to September 30, 2022
Ref: Scrip Code No. 524768

Pursuant to Regulation 13(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are furnishing herewith details of investor grievance of the Company for the quarter ended September 30, 2022, as per the attached Report dated: 15-10-2022 received from RTA, M/s. Link Intime India Pvt Ltd.

Particulars	Quarter ended September 30, 2022
Investor Complaints:	
Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Disposed of during the quarter	Nil
Remaining unresolved at the end of the quarter	Nil

You are kindly requested to take this on record.

Thanking you,

Yours faithfully,
For Emmessar Biotech & Nutrition Limited



Priyanka O. Sharma
Company Secretary
ICSI Membership No.: A52518
Encl: As above

Date: 15.10.2022

To,
Company Secretary
Emmessar Biotech & Nutrition Limited

Sub: Investor Grievance Report for the quarter ended 30.09.2022.

Please refer the below investor grievance details for the period, starting from 01.07.2022 to 30.09.2022.

Investor grievance report for the quarter ended 30.09.2022						
Particulars	SEBI	BSE	NSE	Letters	Mails	Total
Pending at the beginning of the quarter	Nil	Nil	Nil	Nil	Nil	Nil
Received during the quarter	Nil	Nil	Nil	Nil	Nil	Nil
Disposed of during the quarter	Nil	Nil	Nil	Nil	Nil	Nil
Remaining unresolved at the end of the quarter	Nil	Nil	Nil	Nil	Nil	Nil

Thanking You,
For Linkintime India Pvt Ltd



Authorized Signatory